Stock OXIGENE INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company OXiGENE Inc Nasdaq

Equities

US6918284042

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for OXiGENE Inc
Apr. 12 Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 25 Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients CI

Business Summary

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company’s pipeline includes OT-101, CA4P and Oxi4503. OT-101 is antisense against TGF-2 for the treatment of solid tumors with focus on brain cancer in adults and diffuse intrinsic pontine glioma (DIPG) in children. OT-101 is antisense against TGF-2 for the treatment of various viruses, including the SARS and the COVID-19, on its own and in conjunction with other compounds. CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. Oxi4503 is VDA for the treatment of liquid tumors with a focus on childhood leukemia.

Sales per Business

USD in Million2022Weight2023Weight Delta
Biopharmaceutical
100.0 %
0 nan % 0 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 0 100.0 % -

Managers

Managers TitleAgeSince
Vuong Trieu CEO
 Chief Executive Officer 59 19-04-21
Amit Bhupendra Shah DFI
 Director of Finance/CFO 57 19-06-30
Seymour H. Fein CTO
 Chief Tech/Sci/R&D Officer 75 20-01-05
Anthony Maida CTO
 Chief Tech/Sci/R&D Officer 59 20-05-10
Saran Saund PRN
 Corporate Officer/Principal 66 19-10-31

Members of the board

Members of the board TitleAgeSince
Steven W. King BRD
 Director/Board Member 59 20-05-10
Anthony Maida CTO
 Chief Tech/Sci/R&D Officer 59 20-05-10
Vuong Trieu CEO
 Chief Executive Officer 59 19-04-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 399,683,858 180,543,044 ( 45.17 %) 0 45.17 %

Shareholders

NameEquities%Valuation
Vuong Trieu
24.78 %
98,916,746 24.78 % 4 M $
Balaji Bhakta
10.43 %
41,630,811 10.43 % 1 M $
Larn Hwang
5.876 %
23,455,990 5.876 % 844 416 $
Hsiao Chao
4.277 %
17,073,604 4.277 % 614 650 $
Autotelic, Inc.
4.204 %
16,780,384 4.204 % 604 094 $
Saran Saund
4.123 %
16,456,480 4.123 % 592 433 $
Steven W. King
0.8344 %
3,330,647 0.8344 % 119 903 $
Anthony Maida
0.2849 %
1,137,314 0.2849 % 40 943 $
Amit Bhupendra Shah
0.0899 %
358,837 0.0899 % 12 918 $
GAM London Ltd.
0.000104 %
416 0.000104 % 15 $

Company contact information

Oncotelic Therapeutics, Inc.

29397 Agoura Road Suite 107

91301, Agoura Hills

+

http://www.oncotelic.com
address OXiGENE Inc

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.26% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 95.71B
ARGENX SE Stock argenx SE
+0.82% 22.02B
BIONTECH SE Stock BioNTech SE
-17.84% 20.9B
GENMAB A/S Stock Genmab A/S
-9.30% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.63% 15.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.55% 13.86B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.11% 12.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. OTLC Stock
  4. Stock
  5. Company OXiGENE Inc